Research programme: cystic fibrosis therapeutics - CombinatoRx/Cystic Fibrosis Foundation Therapeutics
Latest Information Update: 09 Sep 2010
At a glance
- Originator CombinatoRx; Cystic Fibrosis Foundation Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 04 Feb 2008 Early research development is ongoing
- 06 Jun 2006 Early research in Cystic fibrosis in USA (unspecified route)